Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
Bristol Myers Squibb Completes Acquisition of Mirati Therapeutics, Strengthening and Diversifying Oncology Portfolio
01/23/24, 1:33 PM
Location
lawrencevillesan diegoIndustry
manufacturing
health care
therapeutics
biotechnology
health care
Bristol Myers Squibb has successfully completed the acquisition of Mirati Therapeutics, Inc., further diversifying and strengthening its oncology portfolio. Through this acquisition, Bristol Myers Squibb has added the commercialized lung cancer medicine KRAZATI to its portfolio, as well as several promising clinical assets, reinforcing its commitment to delivering innovative treatments for cancer patients.
Company Info
Location
Lawrenceville, New Jersey, United States
Company info
Bristol Myers Squibb is a global biopharmaceutical company whose mission is to discover, develop and deliver innovative medicines that help patients prevail over serious diseases. For more information about Bristol Myers Squibb, visit us at BMS.com or follow us on LinkedIn, Twitter, YouTube, Facebook, and Instagram.